Pharma announces additional data from APF530 Phase 3 research on CINV A.

A dmae .P. Pharma announces additional data from APF530 Phase 3 research on CINV A.P. Pharma, Inc. , a specialty pharmaceutical organization, today announced additional data from the Company’s Phase 3 research of APF530 for the prevention of chemotherapy-induced nausea and vomiting . The Company presented the today at a poster presentation during the Multinational study results Association of Supportive Treatment in Tumor and the International Culture of Oral Oncology International Symposium in New York. As previously reported, the Phase 3 research showed APF530 was comparable to palonosetron in preventing both severe – and delayed-onset CINV in patients receiving either moderately emetogenic chemotherapy or extremely emetogenic chemotherapy .

This year's winning paper is: ‘Usage of a Bioactive Scaffold to Stimulate Healing also Minimizes Post-Traumatic Osteoarthritis after Medical operation’ by Martha M. Murray MD and Braden C. Fleming PhD. This calendar year's winning paper was from the Hospital for Special Medical procedures in New York and titled ‘Presentation Advancement and Validation of a Pediatric Sports Activity Rating Scale.’ Research authors included: Peter D. Fabricant MD, MPH, Alex Robles BS, Timothy Downey-Zayas BS1, Huong T. Do MA, Robert G. Marx MD, MSc, Roger F. Widmann MD, and Daniel W. Green MD, MS. O'Donoghue Sports Injury Analysis Award This award is given annually to the best general paper that deals with clinical based analysis or human in-vivo study. In 2013 it is directed at authors: Daryl C.